[Edaily Reporter Kim Hyung-il ] #RecensMedical, Inc., a company specializing in precision cooling medical devices, announced on the 20th that it will present a clinical case study on exosome delivery using its veterinary-exclusive precision cooling platform, “VetEase,” at the “London Vet Show 2026” in London, UK.
RecensMedical, Inc. will present a clinical case study on exosome delivery using its veterinary-specific precision cooling platform, “VetEase,” at the “London Vet Show 2026” in the UK. (Photo: RecensMedical, Inc.)
The presentation will take place for 50 minutes starting at 3:40 p.m. local time on the 20th in the exhibitor presentation hall. The topic is the use of exosomes in veterinary dermatology and wound healing. A local British veterinarian is scheduled to share the exosome delivery method utilizing VetEase’s ice-needling technology and case studies from actual clinical practice.
The presenter, Tunde Vaskor Kiss, is the Medical Director of the VetCare Center at the Guernsey Animal Hospital in the United Kingdom and a veterinarian with over 20 years of experience in small animal clinical practice. She has served as a veterinarian, Medical Director, and Regional Manager at major UK animal hospital groups, including MediVet and IVC. She has worked in the fields of veterinary dermatology, surgery, and dentistry, as well as in the clinical operations of animal hospitals, and received the MediVet “Veterinarian of the Year” award in 2018.
Dr. Kishi has been serving as a consulting veterinarian for VetIs since 2025, conducting clinical training and presentations on exosome delivery, cryotherapy, and cryosurgery. In this presentation, he will introduce research trends related to exosome-mediated inflammation regulation and tissue regeneration, and share delivery methods utilizing VetIs’ Ice Needling technology along with case studies from clinical practice.
He will also present specific treatment protocols, clinical observation results, and treatment outcomes. In addition, he plans to outline remaining challenges in verifying clinical efficacy and safety, as well as future plans for protocol standardization and directions for further research.
The London Vet Show is a veterinary conference and exhibition in which the Royal College of Veterinary Surgeons and the Royal Society of Veterinary Surgeons participate as educational partners. Each year, approximately 400 companies and thousands of veterinary professionals attend. Through this presentation, RecensMedical, Inc. aims to share the practical experience accumulated in the Asian market with European veterinarians and potential partners, and to expand its network to enter the European market.
VetIs is currently supplied to seven Southeast Asian regions—including Thailand, Malaysia, Singapore, the Philippines, Vietnam, Cambodia, and Myanmar—through its official distributor, the Pet Innovative Science Center (PISC) in Thailand. In addition, it is distributed in Taiwan, Japan, Hong Kong, China, and South Korea, where the company is accumulating clinical experience with veterinarians across Asia.
RecensMedical, Inc. is a company that has commercialized medical devices used in fields such as transdermal drug delivery and rapid cooling anesthesia, based on technology that enables high-speed, precise control of cryogenic refrigerants. Its dermatological precision cooling device, “TargetCool,” has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance, European CE certification, and medical device approval from the Korean Ministry of Food and Drug Safety. The company is expanding its business into the pet healthcare market through “Vetiz,” which applies the precision cooling technology accumulated in the human medical device sector to the veterinary field.
A representative from RecensMedical, Inc. stated, “It is highly significant that a veterinarian who has been conducting clinical practice in the UK for over 20 years is directly sharing their real-world clinical experience,” adding, “Since the field of exosome applications still requires standardization and further validation, we will focus on building clinical evidence in collaboration with practicing veterinarians.”
The representative added, “Building on the foundation we’ve established in Asia, we will expand our network with European veterinarians and partners to ensure that Betiz becomes a trusted solution in the global veterinary field.”
As the spread of fraud and misinformation using artificial intelligence (AI) continues to rise, investment is flowing into European startups that verify AI-generated content. The scope of investment i…
“Limcato,” developed by Curocell Inc. and Korea’s first domestically produced chimeric antigen receptor T-cell (CAR-T) therapy, is set to be covered by the National Health Insurance. This is expected …
CJ ENM CO., Ltd.(035760)has filed a petition for a preliminary injunction with the court, asking it to prevent LG HelloVision(037560)from suspending broadcasts on its four channels.
(Photo: CJ ENM …